Derma Sciences Inc. (OTCBB: DSCI) manufactures and markets advanced wound-care products around the world. The company today announced it will commence the sale of its novel MOBILITY1 Intermittent Pneumatic Compression Therapy Device beginning in October. The commercial launch will allow the company to target the nearly 7 million people afflicted with chronic venous insufficiency.
Derma Sciences will launch MOBILITY 1 after introducing the product to vascular surgeons at the 9th Annual New Cardiovascular Horizons (NCVH) Conference, September 10-13, 2008, in New Orleans. MOBILITY 1 is used for the treatment of chronic venous insufficiency, venous leg ulcers, lymphadema, the prevention of deep vein thrombosis, and numerous other indications.
Derma Sciences CEO Ed Quilty said MOBILITY 1 is the only product of its kind to answer the unmet needs among mobile patients with unfavorable results as a result of traditional static compression products such as stockings and compression wraps.
“This is another significant milestone for Derma as we continue to launch novel and important new technologies into the advanced wound care market … Allowing these patients to continue on with their normal lifestyle, getting them back to work sooner than later, will be a significant advantage over other pneumatic devices,” Quilty stated in the press release.
“This should help drive efficacy, and potentially reduce the number of active leg ulcers and complications associated with these ulcers. Finally, we are excited to add another significant new product into our line, now that our sales force is up and running with our successful launch of MEDIHONEY. This represents another step in the implementation of our strategic plan to drive shareholder value through the launch of novel, higher margin technologies,” Quilty continued.
MOBILITY1 is based on two patents that allow the compressed air to be driven while patients move about. This allows them to continue with their typical lifestyle. The device is equipped with a small compressor that can be used while patients are at rest.
Let us hear your thoughts below: